Beth Kirkpatrick, M.D.
Professor of Medicine, Infectious Disease Medicine
Department of Medicine
1996-1999 Fellowship, Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD
1997 The Gorgas Certification in Tropical Medicine and Travelers' Health. Instituto de Medicina Tropical Alexander Von Homboldt
1995-1996 Chief Resident and Clinical Instructor, Internal Medicine, University of Rochester
Rochester General Hospital, Rochester, New York
1992-1995 Internship and Residency, Internal Medicine, University of Rochester, Rochester, New York
1988-1992 M.D., Albany Medical College. Albany, New York
1984-1988 B.S., Bates College, Lewiston, Maine/ Majors in Biology and Political Science.
Vaccine Development, Human Immunology.
Professor of Medicine, University of Vermont College of Medicine
Adjunct Professor of Microbiology and Molecular Genetics, University of Vermont College of Medicine
Attending Physician, Infectious Diseases, UVM Medical Center
2015-2019 Bill and Melinda Gates Foundation. Using Cryptosporidium human challenge models to Advance Therapeutics and Vaccines. Principal Investigator.
2015-2018 Bill and Melinda Gates Foundation. Rotavirus Vaccine Underperformance and Correlates of Protection. Principal Investigator.
2014-2017 Bill and Melinda Gates Foundation. Characterizing the Immunoprotective and Immunopathogenic Responses to Dengue Viruses using the Dengue Human Infection Model. Co-principal investigator (Co-PI, with Anna Durbin, Principal Investigator, Johns Hopkins).
2014 PaxVax. A Phase III Randomized, Double-blind, Placebo-controlled study in older adults to assess immunogenicity and clinical acceptability of a single-dose of the live oral cholera vaccine candidate PXVX0200 Vibrio cholera 01 Serotype Inaba Vaccine strain CVD103-HgR. Site co-Principal Investigator (with CE Lyon).
2013-2015 PaxVax. A Phase III Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose of Live Oral Cholera Vaccine Candidate, PXVX0200 CVD 103-HgR Strain, in Preventing Cholera following Challenge with Vibrio cholerae O1 El Tor Inaba 10 Days or 3 Months after Vaccination. Site Principal Investigator (with CE Lyon).
2010-2015 Bill and Melinda Gates Foundation. Exploration of the Biologic Basis for the Underperformance of Oral Polio and Rotavirus Vaccination in Bangladesh and India. Co-Principle Investigator (with William Petri Jr.MD, PhD, Principal Investigator).
2009-2019 National Institutes of Health AO2008011.Operation of a Facility for the study of infectious agents, vaccines and antimicrobials in adult and pediatric human subjects. Federal Contract with Johns Hopkins University, UVM Site Principal Investigator (with Johns Hopkins Site Principal Investigator, Anna Durbin.
2012 Bailey K. Ashford Medal. American Society of Tropical Medicine. Awarded for distinguished work in tropical medicine to a worker in his or her mid-career
2012 University of Vermont, College of Medicine. White Coat Ceremony. Key note speaker
2010 Professor in Residence, Infectious Disease Institute, Makerere University, Kampala, Uganda
2006 University of Vermont Frymoyer Scholarship, "Global Health Education and Training for Health Care Professionals at UVM"
2003 University of Vermont, New Research Initiative, "Disease Severity in Cryptosporidiosis: Association with Parasite genotype and Class II Human Leukocyte Antigens."
2000 Fletcher Allen Health Care, Patient Orientated Research Award, Principal Investigator, Streptococcal Virulence Factors
1999 The Pearl M. Stetler Fund Research Fellowship, Johns Hopkins University School of Medicine
1998 The Pearl M. Stetler Fund Research Fellowship, Johns Hopkins University School of Medicine
1997 Gorgas Institute Memorial Fellowship, The American Society of Tropical Medicine and Hygiene
1997 Infectious Disease Society of America, Fellow's Abstract Award
Beth D. Kirkpatrick, Stephen S. Whitehead, Kristen K. Pierce, Cecilia M. Tibery, Palmtama Grier, Noreen Hynes, Catherine J. Larsson, Beulah Sabundao, Kawswar Talaat, Marya P. Carmolli, Catherine J. Luke, Sean A. Diehl, Anna P. Durbin. The live attenuated tetravalent dengue vaccine TV003 elicits complete protection against dengue virus serotype 2 infection in a human challenge mode. Science Translational Medicine 2016.
Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection with Vibrio cholera 01 El Tor. Clinical Infectious Diseases. 2016. Accepted, in press.
Durbin AP*, Kirkpatrick BD*, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra E, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. [*shared first authors] A 12-month interval dosing study in adults indicates that a single dose of the NIAID tetravalent dengue vaccine induces a robust neutralizing antibody response. Journal of Infectious Diseases. 2016. Accepted, in press.
Mychaleckyj JC, Haque R, Colgate ER, Oberste S, Weldon W, Carmolli MP, Qadri F, Dickson DM, Nayak U, Taniuchi M, Zaman K, Alam K, Diehl SA, PROVIDE study teams, Kirkpatrick BD, Petri WA Jr. Effect of Substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: an open-labeled randomized controlled trial. Vaccine. Accepted, in press.
Colgate ER, Haque R, Carmolli MP, Dickson DM, Carmolli MP, Mychaleckyj JC, Nayak U, Qadri F, Alam K, Walsh MC, Diehl SA, Zaman K, Petri WA Jr., Kirkpatrick BD. The Impact of Serum Zinc and Delayed Dosing on Rotavirus Gastroenteritis and Rotavirus Oral Vaccine Performance in Bangladeshi Infants. Clinical Infectious Diseases. Submitted.
Donowitz JR, Haque R, Kirkpatrick BD, Alam M, Lu M, Kabir M, Kakon SH, Islam BZ, Afreen S, Musa A, Khan SS, Colgate ER, Carmolli MP, Ma JZ, Petri WA. Small intestinal bacterial overgrowth and environmental enteropathy in Bangladeshi children. MBio 2016; 7 (1): e02102-15.
Kirkpatrick BD, Mychaleckyj JC. Polio Eradication: Inching forward, with safety nets. Lancet Infectious Diseases [editorial] 2015; 15: 1244-45.
Kirkpatrick BD*, Durbin AP*, Pierce KK, Carmolli MP, Tibery C, Grier P, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik J, Luke C, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. *shared first author. Robust and balanced immune responses to all four dengue serotypes following a single dose of a live-attenuated tetravalent vaccine administered to healthy flavivirus-naïve adults. Journal of Infectious Diseases 2015; 212: 702-12 [with editorial].
Kirkpatrick BD, Colgate ER, Mychaleckyj JC, Haque R, Dickson DM, Carmolli MP, Nayak U, Taniuchi M, Naylor C, Qadri F, Ma JZ, Alam M, Walsh MC, Diehl SA, Petri WA Jr. The Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) study: Description of Methods of an Interventional Study Designed to Explore Complex Biologic Problems. American Journal Tropical Medicine and Hygiene 2015; 92 (4): 744-51.
Weiskopf D, Angelo MA, Bangs DJ, Sidney J, Paul S, Peters Bjoern Peters, deSilva AD, Lindow JC, Whitehead SS, Durbin A, Kirkpatrick BD, Sette A. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes and are similar in magnitude and breadth to those following natural infection. Journal of Virology 2015; 89 (10): 120-128.